Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity

Kariofyllis Karamperis*, Sonja Katz, Federico Melograna, Francesc P. Ganau, Kristel Van Steen, George P. Patrinos*, Oscar Lao*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
6 Downloads (Pure)

Abstract

Genetic ancestry plays a major role in pharmacogenomics, and a deeper understanding of the genetic diversity among individuals holds immerse promise for reshaping personalized medicine. In this pivotal study, we have conducted a large-scale genomic analysis of 1,136 pharmacogenomic variants employing machine learning algorithms on 3,714 individuals from publicly available datasets to assess the risk proximity of experiencing drug-related adverse events. Our findings indicate that Admixed Americans and Europeans have demonstrated a higher risk of experiencing drug toxicity, whereas individuals with East Asian ancestry and, to a lesser extent, Oceanians displayed a lower risk proximity. Polygenic risk scores for drug-gene interactions did not necessarily follow similar assumptions, reflecting distinct genetic patterns and population-specific differences that vary depending on the drug class. Overall, our results provide evidence that genetic ancestry is a pivotal factor in population pharmacogenomics and should be further exploited to strengthen even more personalized drug therapy.

Original languageEnglish
Article number110916
JournaliScience
Volume27
Issue number10
DOIs
Publication statusPublished - 18 Oct 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s)

Fingerprint

Dive into the research topics of 'Genetic ancestry in population pharmacogenomics unravels distinct geographical patterns related to drug toxicity'. Together they form a unique fingerprint.

Cite this